Compare Samsara Inc (IOT) vs 10X Genomics Inc (TXG) Price & Performance

Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2027 results, beating earnings estimates with $0.20 EPS versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.

The stock offers upside to the $51.15 consensus price target, driven by solid fundamentals and institutional accumulation. However, elevated valuation multiples (P/E 270.07, P/S 12.79) and negative net income in 2025 pose risks if growth moderates. Positive cash flow trends and a 75% buy rating from analysts support a constructive outlook, though investors should monitor competitive pressures and execution on profitability goals.

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.